Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine

Basim Mohammad Ayesh1,1, Ahmed Shaker Abu Shaaban2,2, Abdalla Asaf Abed3,3

  • 1Department of Laboratory Medical Sciences, Faculty of Applied Sciences, Alaqsa University, Gaza, Palestine.

Future Science OA
|March 24, 2018
PubMed

Insights

The international warfarin pharmacogenetics consortium algorithm accurately predicts stable warfarin dose in Palestinian patients. This pharmacogenetic approach offers a reliable method for personalized warfarin dosing in this population.

Area of Science:

  • Pharmacogenetics
  • Clinical Pharmacology
  • Genomics

Background:

  • Warfarin dosing requires careful management due to its narrow therapeutic index.
  • Genetic variations in CYP2C9 and VKORC1 significantly influence warfarin metabolism and response.
  • Predictive algorithms aim to optimize warfarin dosage for individual patients.

Purpose of the Study:

  • To assess the applicability of a warfarin pharmacogenetics algorithm for predicting stable warfarin dose (WSD) in Palestinian patients.
  • To compare the performance of the international warfarin pharmacogenetics consortium algorithm against clinical and fixed-dose algorithms.

Main Methods:

  • Retrospective calculation of warfarin doses for 101 Palestinian patients using three distinct models.
  • Evaluation of algorithm performance in a subset of 47 patients who had achieved a stable warfarin dose.
  • Analysis included CYP2C9*2, *3, and VKORC1-1639G>A allele frequencies.

Main Results:

  • The frequency of CYP2C9*2, *3, and VKORC1-1639G>A alleles in the study population was 13.6%, 0.0%, and 46.5%, respectively.
  • The international warfarin pharmacogenetics consortium algorithm demonstrated superior reliability with a Mean Absolute Error (MAE) of 8.9 ± 1.4 and R² of 0.350.
  • Both the clinical algorithm (MAE = 10.4 ± 1.4; R² = 0.128) and the fixed-dose algorithm (MAE = 11.1 ± 1.7) showed lower reliability.

Conclusions:

  • The international warfarin pharmacogenetics consortium algorithm is a reliable tool for predicting stable warfarin dose in the Palestinian population.
  • Pharmacogenetic-guided dosing can improve warfarin therapy management in this demographic.
  • Further validation in larger cohorts is recommended to solidify these findings.
Abstract

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
2
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
4
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
231
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
3
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
429
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
3